GlaxoSmithKline PLC (GSK.L) Key Developments | Reuters.com
Edition:
United States

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,600.00GBp
1 Jul 2016
Change (% chg)

-4.50p (-0.28%)
Prev Close
1,604.50p
Open
1,616.00p
Day's High
1,621.00p
Day's Low
1,581.00p
Volume
13,524,317
Avg. Vol
8,812,548
52-wk High
1,621.00p
52-wk Low
1,210.27p

Latest Key Developments (Source: Significant Developments)

Mylan launches generic version of GSK's avodart capsules
Friday, 24 Jun 2016 11:44am EDT 

Mylan NV: Mylan launches generic Avodart® capsules .U.S. launch of Dutasteride capsules, 0.5 mg, generic version of GlaxoSmithKline's avodart capsules.  Full Article

GlaxoSmithKline says lung drug meets late-stage study goals
Monday, 20 Jun 2016 02:02am EDT 

Glaxosmithkline Plc : Fulfil study results closed triple eu . Fulfil study shows superiority of closed triple combination therapy ff/umec/vi versus symbicort turbohaler . Data supports regulatory submission by gsk in europe by end of 2016 . Positive top-line results from phase iii study of fluticasone furoate/umeclidinium/vilanterol . Study met its two co-primary endpoints .Study demonstrated statistically significant improvements in lung function and health- related quality of life.  Full Article

GlaxoSmithKline says vaccines chairman Slaoui to retire in 2017
Tuesday, 14 Jun 2016 05:58am EDT 

Glaxosmithkline Plc : Moncef Slaoui, Chairman, Vaccines, has indicated to board his intention to retire from company in 2017 . Board supports Dr Slaoui's decision and has agreed he will retire on June 30 2017 .Slaoui will remain member of board until March 31 2017; from April 1 2017 until retirement will serve as an advisor to GSK.  Full Article

ViiV Healthcare says FDA approves sNDA for dolutegravir
Friday, 10 Jun 2016 09:10am EDT 

Viiv Healthcare Ltd : ViiV Healthcare announces FDA approval to lower weight limit for dolutegravir in children and adolescents living with HIV . FDA has approved a supplemental new drug application for dolutegravir 10mg and 25mg oral tablets, reducing weight limit . FDA approved supplemental new drug application for dolutegravir oral tablets, reducing weight limit to at least 30kg Further company coverage: [IPO-VIHL.L] (Bengaluru Newsroom: +91 80 6749 1136).  Full Article

GSK rheumatoid arthritis, SLE drug meets late stage study goal
Wednesday, 8 Jun 2016 05:38am EDT 

Glaxosmithkline Plc :New phase III data shows greater treatment response with GSK's Benlysta (Belimumab) versus placebo in patients with highly active SLE.  Full Article

Mylan launches generic rythmol sustained-release capsules
Thursday, 2 Jun 2016 07:00am EDT 

Mylan NV : Mylan launches generic rythmol sustained-release capsules .U.S. launch of propafenone hydrochloride extended-release capsules USP, 225 mg, 325 mg, 425 mg, a generic version of glaxosmithkline's Rythmol Sr.  Full Article

GlaxoSmithkline accelerates filing of COPD triple-therapy drug
Thursday, 2 Jun 2016 02:00am EDT 

Glaxosmithkline Plc : Regulatory update on us filing plans for closed triple combination therapy ff/umec/vi in patients with copd .Acceleration of filing of us new drug application now expected by end of 2016.  Full Article

Regulus expands clinical trial collaboration with GSK
Wednesday, 1 Jun 2016 08:00am EDT 

Regulus Therapeutics Inc : Ongoing phase ii rg-101 and oral gsk2878175 combination study on track to report interim results by year-end .Regulus expands clinical trial collaboration with gsk.  Full Article

Fitch downgrades GSK to 'A' with stable outlook
Friday, 27 May 2016 11:38am EDT 

Fitch: Fitch downgrades GSK to 'A', outlook stable . Downgrade reflects fitch's view of a weakening business risk profile for GlaxoSmithKline PLC . Has also downgraded senior unsecured rating for debt issued under Glaxosmithkline Capital PLC to 'A' from 'A+' .Has assigned a senior unsecured rating of 'A' to debt issued by GlaxoSmithKline Capital Inc.  Full Article

GlaxoSmithKline appoints Vivienne Cox to board
Friday, 27 May 2016 09:56am EDT 

Glaxosmithkline Plc : Board and committee changes .Dr Vivienne Cox, CBE, has been appointed to board of company as a non-executive director with effect from 1 July 2016.  Full Article

BRIEF-Mylan launches generic version of GSK's avodart capsules

* U.S. launch of Dutasteride capsules, 0.5 mg, generic version of GlaxoSmithKline's avodart capsules Source text for Eikon: Further company coverage: